Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Pall v. Hemasure

This article was originally published in The Gray Sheet

Executive Summary

Pall v. Hemasure: Pall files suit alleging that Hemasure's LeukoNet leukocyte removal device for filtering donated blood infringes upon Pall patents covering "the processing of blood or blood products." LeukoNet was cleared by FDA in June 1995 ("The Gray Sheet" Jan. 9, 1995, In Brief). The suit, filed in the U.S. District Court for the Eastern District of New York, seeks an injunction against Hemasure as well as damages. Hemasure says it does not believe LeukoNet infringes "any valid patent rights." Separately, Hemasure announces that it has entered into a collaborative agreement with the Pacific Northwest Regional Blood Services of the American Red Cross, Portland, Oregon, to study the effectiveness of using LeukoNet technology "to remove tumor cells from peripheral stem cell concentrates which are used in certain cancer therapies"...

You may also be interested in...



Did Sarepta Need To Tell Investors About Its Vyondys 53 Dispute Resolution Request?

Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.

Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning

Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.

Horizon's Teprotumumab Breezes Through US FDA Adcom, But Safety Questions Remain

Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.

UsernamePublicRestriction

Register

MT005497

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel